Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JiangXi Tianxin Pharmaceutical CoSHSE:603235 +0.74%80 Return-on-Tangible-Asset is 11.19% as of Jun. 2026, which is 48% below its 10-year median of 21.49. GuruFocus rates SHSE:603235 with a GF Score™ of 80/100 and a GF Value™ of ¥30.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 2,002 Consumer Packaged Goods companies, JiangXi Tianxin Pharmaceutical Co ranks better than 78.92% on this metric.
The historical rank and industry rank for JiangXi Tianxin Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:603235'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.36 Med: 21.49 Max: 40.7
Current: 9.36
During the past 8 years, JiangXi Tianxin Pharmaceutical Co's highest Return-on-Tangible-Asset was 40.70%. The lowest was 9.36%. And the median was 21.49%.
SHSE:603235's Return-on-Tangible-Asset is ranked better than 78.92% of 2002
companies
in the Consumer Packaged Goods industry
Industry Median: 3.52
vs SHSE:603235: 9.36
JiangXi Tianxin Pharmaceutical Co (SHSE:603235) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
JiangXi Tianxin Pharmaceutical Co Return-on-Tangible-Asset Related Terms
JiangXi Tianxin Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JiangXi Tianxin Pharmaceutical Co Return-on-Tangible-Asset Chart
SHSE:603235 vs KHC, GIS: Return-on-Tangible-Asset Comparison
For the Packaged Foods subindustry, JiangXi Tianxin Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JiangXi Tianxin Pharmaceutical Co Return-on-Tangible-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, JiangXi Tianxin Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where JiangXi Tianxin Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 11.19% mean?
JiangXi Tianxin Pharmaceutical Co (SHSE:603235) has a Return-on-Tangible-Asset of 11.19% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on JiangXi Tianxin Pharmaceutical Co and its competitors. This is 48% below median its historical median of 21.49. Over the past decade, JiangXi Tianxin Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 9.36 to 40.70. According to the industry distribution chart, JiangXi Tianxin Pharmaceutical Co ranks #422 out of 2002 companies in the Consumer Packaged Goods industry, placing it in the top 21.1%.
Is JiangXi Tianxin Pharmaceutical Co's Return-on-Tangible-Asset too high?
JiangXi Tianxin Pharmaceutical Co's current Return-on-Tangible-Asset of 11.19% is 48% below median its 10-year median of 21.49. Over the past 10 years, this metric has ranged from a low of 9.36 to a high of 40.70. The Consumer Packaged Goods industry median Return-on-Tangible-Asset is 3.52. JiangXi Tianxin Pharmaceutical Co's value of 11.19% is 217.9% above this industry median. Based on the distribution chart, JiangXi Tianxin Pharmaceutical Co ranks #422 out of 2002 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, JiangXi Tianxin Pharmaceutical Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JiangXi Tianxin Pharmaceutical Co's Return-on-Tangible-Asset compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JiangXi Tianxin Pharmaceutical Co ranks #422 out of 2002 companies for Return-on-Tangible-Asset. This places JiangXi Tianxin Pharmaceutical Co in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.52. JiangXi Tianxin Pharmaceutical Co's value of 11.19% is 217.9% above this benchmark. Historically, JiangXi Tianxin Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 9.36 to 40.70 over the past decade. While the company's 10-year median is 21.49 vs. the industry median of 3.52, JiangXi Tianxin Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Consumer Packaged Goods company?
The median Return-on-Tangible-Asset among Consumer Packaged Goods companies is 3.52, based on 2,002 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JiangXi Tianxin Pharmaceutical Co's current Return-on-Tangible-Asset of 11.19% is 217.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on JiangXi Tianxin Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Asset is 3.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JiangXi Tianxin Pharmaceutical Co's current Return-on-Tangible-Asset is 11.19%, which is 48% below median its own 10-year median of 21.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JiangXi Tianxin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, JiangXi Tianxin Pharmaceutical Co (SHSE:603235) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥30.52, compared to a current price of ¥24.62 — trading 19.3% below its estimated fair value. The current Return-on-Tangible-Asset is 11.19%, which is 48% below median its 10-year median of 21.49 and 217.9% above the Consumer Packaged Goods industry median of 3.52. JiangXi Tianxin Pharmaceutical Co's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For JiangXi Tianxin Pharmaceutical Co (SHSE:603235), the current Return-on-Tangible-Asset is 11.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JiangXi Tianxin Pharmaceutical Co (SHSE:603235) Overvalued in 2026?
Based on GuruFocus' analysis, JiangXi Tianxin Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥24.62 is trading 19.3% below its estimated GF Value™ of ¥30.52.
GuruFocus considers JiangXi Tianxin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603235:
Return-on-Tangible-Asset: 11.19% (48% below median its 10-year median of 21.49)
GF Value™: ¥30.52 vs. price of ¥24.62 (19.3% below fair value)
Industry Position: 217.9% above the Consumer Packaged Goods median (#422 of 2002)
No single metric tells the full story. See the SHSE:603235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603235 has been successfully added to your 
